title: Safety and Efficacy of Itolizumab in the Treatment of Psoriasis: A Case Series of 20 Patients.
abstract: Psoriasis is a common, chronic, relapsing/remitting, immune-mediated skin disease that causes itchy skin with silvery scales. It is characterized by thickened red erythematous plaques covered with silvery scales. Biological therapies have been recently introduced for patients with psoriasis in India. The biological therapies contain protein biomolecules which can be employed to target specific immune or genetic mediator of a pathophysiological process. Here, we share our clinical experience of managing 20 patients with moderate to severe psoriasis by itolizumab a humanized IgG1 monoclonal antibody. Eighteen patients achieved Psoriasis Area and Severity Index (PASI) 75 response after receiving 10 infusion of itolizumab (at the completion of treatment). Out of 18 patients 4 patients had achieved PASI 95 response and 10 patients had achieved PASI 90 response. There was no adverse event reported during the treatment period. Itolizumab was found effective and safe in the treatment of moderate to severe psoriasis patients.
authors.affiliation: Consultant, Department of Dermatologist, Dr. Anchala's Skin Institute and Research Centre , Hyderabad, Telangana, India .
authors.forename: Anchala
authors.initials: A
authors.lastname: Parthasaradhi
keywords: Biological; Itolizumab; PASI 75; Skin disease